Bladder Capacity as Objective Measure of Intravesical Treatment of Newly Diagnosed IC
Status:
Completed
Trial end date:
2020-03-30
Target enrollment:
Participant gender:
Summary
A comparative study of subjective outcomes following intravesical treatment of interstitial
cystitis (IC) is lacking in the literature. Furthermore, an objective measure to determine
the efficacy of intravesical treatment for interstitial cystitis has yet to be defined.
Change in bladder capacity following therapy has been investigated; however, a formal
statistical analysis of its utility in determining efficacy has yet to be performed. The
primary objective of this prospective, randomized study is to determine whether there is a
significant difference in subjective improvement in IC symptoms in women with newly diagnosed
IC when treated with either dimethyl sulfoxide (DMSO) or bupivacaine, triamcinolone, and
heparin (BTH) instillations. The secondary objective is to determine whether change in
bladder capacity can be used as an objective measure of response to intravesical therapy for
newly diagnosed interstitial cystitis. Our long-term goals are to improve the scientific
understanding of therapy for interstitial cystitis, to improve patient counseling prior to
initiation of treatment, and to better identify patients likely to receive inadequate relief
of symptoms following intravesical treatment so that an alternative treatment can be pursued.